Hit Identification Phase
Our proprietary technology platforms allow us to find hits for you that are free of undesirable chemical functionality, and with highly developable molecular and physicochemical properties. Good-quality initial hits greatly improve the probability that a hit can be successfully and quickly optimised to a candidate drug molecule.
Domainex’s proprietary virtual screening platform, identifies potential chemical starting points for your drug discovery programme in a rapid and cost-effective manner. This platform can be used in protein structure-based or ligand-based modes. When protein structural data is not available for your target, it may be possible for Domainex to build a homology model for drug design purposes.
Visit our LeadBuilder page to find out more.
Our unique, integrated Fragment-Based Drug Design platform, rapidly identifies high-quality fragment hits. Central to the success of this platform is the continuous evolution of our screening libraries. Our computational chemists ensure not only good coverage of chemical space but also optimisation of additional characteristics, such as shape, flexibility, three-dimensional character and pharmacophoric coverage. They also advise our chemists how to develop fragment hits into more potent compounds by designing compound arrays that explore potential protein-ligand interactions.
Visit our FragmentBuilder page to find out more.
At these stages in your project, our computational chemists will give you valuable insights into compound design, scaffold hopping, property profiling and the analysis of structure-activity relationships (SARs).
Our CADD team can analyse structural information about your nominated target, and design and help you prioritise ideas for prospective ligands. We can also overlay your target on related protein structures, using these comparisons to identify any differences which may enable the design of selective compounds.
Examples of projects where we have applied SBDD include:
- Der p 1: Protease inhibitors for the treatment of asthma
- Tankyrase: Inhibitors for the treatment of solid tumours and
- TBK1/IKKε: Kinases inhibitors for the treatment of interferonopathies
Ligand-Based Drug Design
Our CADD experts will work closely with you to analyse and interpret your data – for example, they could cluster your dataset and identify a subset of molecules for further development.
If you have a small dataset and want to further explore SARs around these chemotypes, our CADD team can search our curated proprietary databases of commercially available suppliers for nearest-neighbour analogues, which can be subsequently purchased and tested.
Domainex also has several state-of-the-art property prediction tools, such as the ACDLabs software, that allows us to compare the predicted values for your compounds with those measured by our physical chemists. These comparisons can lead to improved predictive models for your series, and we can use these to devise structure-property relationships that are extremely informative in guiding drug design into the right property space.
Domainex can also offer additional computational chemistry services through its alliance with Cresset. Cresset offers a range of solutions including approaches centred on the application of the eXtended Electron Distribution (XED) force field to the design of new small molecule bioactive compounds. The XED approach improves traditional molecular mechanics by using a complex description of atoms to model charge away from atomic centres. This enables a more detailed description of electrostatics and excellent reproduction of intermolecular interactions.